← Back to the Fat Loss Planner 📖 Beyond the Book

By Nir Nagar · Fat Loss, For Real

Beyond the Book: Medications and Gray-Market Substances

These two special chapters extend Fat Loss, For Real: The Evidence-Based Guide for Women and Men. They cover prescription weight-loss medications, bariatric surgery, and the risks of illegal and gray-market substances. Because this field changes quickly, we keep these chapters here, where they can be updated as new approvals and trial results appear.

Chapter 1: Prescription Medications for Weight Loss

Prescription medications can be helpful tools when they are selected carefully, monitored properly, and paired with nutrition, training, sleep, and behavioral change. They are not stand-alone fixes. This chapter summarizes the major options, what they do, how well they work, safety notes that matter in real life, and how to integrate them with your program.

Main Drug Categories

1) GLP-1 receptor agonists and dual agonists

Current options

  • Semaglutide: Ozempic for type 2 diabetes (also approved to reduce heart and kidney risk), Wegovy for chronic weight management, for cutting heart attack and stroke risk in people with heart disease (2024), and for the liver disease MASH (2025)

  • Liraglutide: Victoza for type 2 diabetes, Saxenda for weight management; lower-cost generic liraglutide for both uses is now available in the US

  • Tirzepatide: Mounjaro for type 2 diabetes, Zepbound for weight management and, since December 2024, moderate-to-severe obstructive sleep apnea in adults with obesity; a dual GLP-1 and GIP agonist

  • Oral semaglutide: Rybelsus (lower doses) for type 2 diabetes, and since December 2025 the higher-dose Wegovy pill (25 mg) for weight management. Because it slows gastric emptying, it can delay absorption of some oral drugs.

  • Orforglipron: Foundayo, a once-daily small-molecule GLP-1 pill approved for weight management in 2026, with no food or water timing rules. See the 2026 Update below.

Mechanism
These medicines mimic incretin hormones that increase satiety, slow stomach emptying, and improve insulin dynamics. The result is lower calorie intake and better post-meal glucose control.

Typical effectiveness in randomized trials

  • Semaglutide: about 10 to 15 percent mean weight loss by 68 weeks

  • Liraglutide: about 5 to 10 percent by 56 weeks

  • Tirzepatide: about 15 to 22 percent by 72 weeks

  • Oral semaglutide 25 mg: about 14 percent by 64 weeks

  • Orforglipron: about 11 to 12 percent by 72 weeks

Individual responses vary. Lifestyle alignment determines how durable the results are.

Common side effects
Nausea, vomiting, diarrhea or constipation, abdominal discomfort, early fullness, fatigue, lightheadedness. These are usually dose-related and improve with slow titration.

Important safety and practical notes

  • Hypoglycemia is uncommon when used alone but risk increases if taken with insulin or a sulfonylurea. Doses of those agents often need reduction.

  • Diabetic retinopathy can worsen with rapid glucose improvement on semaglutide. People with existing retinopathy need closer monitoring.

  • Oral contraceptives (tirzepatide and orforglipron). Because gastric emptying slows, effectiveness of oral contraceptives may be reduced when starting tirzepatide or orforglipron (Foundayo) and after dose increases. Use a back-up method for 4 weeks (tirzepatide) or 30 days (orforglipron) after starting and after each dose increase.

  • Gallbladder. Rapid weight loss and GLP-1 drugs both increase gallstone risk. Report right-upper-quadrant pain or jaundice.

  • Pancreatitis. Stop and seek care if severe persistent abdominal pain occurs.

  • Thyroid C-cell tumor warning. These drugs carry a boxed warning based on thyroid C-cell tumors seen in rodents given GLP-1 drugs (for orforglipron the warning is class-based, since it did not cause these tumors in rodents). They are contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.

  • Peri-procedure. Discuss timing with your clinician before anesthesia or GI procedures because delayed gastric emptying raises aspiration risk.

  • Pregnancy planning. Stop in advance of trying to conceive. Ask your clinician for the appropriate washout period for the specific drug.

  • Titration tips. Increase doses slowly. If nausea persists, ask your prescriber about staying at the current dose longer or stepping back temporarily; smaller meals and avoiding very fatty foods and alcohol also help.

Cost
Out-of-pocket costs can be high. Coverage and prior authorization rules change frequently. Ask about patient assistance programs if needed.

2) Fat absorption inhibitor

Orlistat: Xenical by prescription, Alli over-the-counter

Mechanism
Blocks pancreatic lipase so about 30 percent of dietary fat is not absorbed.

Typical effectiveness
About 5 to 8 percent body weight reduction over 1 to 2 years when combined with a low-fat diet. Weight regain is common if stopped without lifestyle changes.

Common side effects
Oily stools, fecal urgency or incontinence, flatulence with discharge, cramping. These effects map directly to how much fat is in the meal.

Practical and safety notes

  • Keep dietary fat below about 30 percent of calories to limit GI effects.

  • Take a multivitamin containing vitamins A, D, E, and K at bedtime at least 2 hours after orlistat.

  • Separate from cyclosporine and levothyroxine by several hours and monitor levels as appropriate.

  • Social planning matters because meals high in fat will predictably cause symptoms.

3) Centrally acting appetite suppressants and combinations

Phentermine
Short-term sympathomimetic that reduces appetite through norepinephrine pathways.

  • Effectiveness: about 3 to 5 percent more weight loss than placebo in the short term.

  • Side effects: increased heart rate and blood pressure, insomnia, anxiety, dry mouth, constipation.

  • Notes: avoid in uncontrolled hypertension, cardiovascular disease, hyperthyroidism, glaucoma, or with MAOIs. Potential for misuse in susceptible individuals.

Phentermine/Topiramate ER (Qsymia)
Combination of a stimulant with topiramate, which also reduces appetite.

  • Effectiveness: about 8 to 12 percent by 56 weeks.

  • Side effects: as above for phentermine plus paresthesias, dysgeusia, cognitive slowing.

  • Notes: teratogenic. Requires effective contraception and monthly pregnancy testing in people who can become pregnant. Taper rather than abrupt stop to avoid seizures.

Naltrexone/Bupropion ER (Contrave)
Targets reward and appetite circuits.

  • Effectiveness: about 5 to 8 percent by 56 weeks.

  • Side effects: nausea, headache, dizziness, constipation, insomnia.

  • Notes: contraindicated in seizure disorders or abrupt alcohol/benzodiazepine withdrawal, with chronic opioid therapy or acute opioid use, in uncontrolled hypertension, or with bulimia or anorexia nervosa. Bupropion lowers seizure threshold, and the label carries a boxed warning for suicidal thoughts and behaviors, so report mood changes promptly.

2026 Update: New Options and What Is Coming

The field of weight-loss medication is changing faster than any other area covered here. This section summarizes the status as of September 2026. Approvals, prices, and availability differ by country and change often, so confirm the current situation with your clinician or pharmacist.

Newly approved in the United States

  • Oral semaglutide 25 mg (Wegovy pill): approved in December 2025 as the first GLP-1 pill specifically for weight management. In the OASIS 4 trial, people lost about 14 percent of body weight over 64 weeks (about 17 percent among those who took it as prescribed), compared with about 2 percent on placebo. It is taken once daily on an empty stomach with a small amount of plain water (no more than 4 ounces, about 120 mL), waiting at least 30 minutes before eating, drinking, or taking other oral medicines.

  • Orforglipron (Foundayo): approved in April 2026. It is a small-molecule GLP-1 pill, not a peptide, so it can be taken without food or water restrictions. In the ATTAIN-1 trial, the highest dose produced about 11 percent weight loss over 72 weeks, compared with about 2 percent on placebo (about 12 versus 1 percent among people who stayed on treatment).

  • Higher-dose semaglutide 7.2 mg (Wegovy HD): approved in March 2026, after earlier approval in Europe and the UK. In the STEP UP trial, it produced about 21 percent weight loss over 72 weeks among people who took it as prescribed, compared with about 17.5 percent on the standard 2.4 mg dose.

How the injectables compare head to head

In the SURMOUNT-5 trial, tirzepatide produced about 20 percent weight loss over 72 weeks, compared with about 14 percent for semaglutide 2.4 mg. Waist circumference fell by about 18 cm and 13 cm, respectively.

On the horizon

  • CagriSema (cagrilintide plus semaglutide): a weekly injection combining an amylin analog with semaglutide. It produced about 20 percent weight loss over 68 weeks in the REDEFINE 1 trial (about 23 percent among people who took it as prescribed). It is under FDA review, with a decision expected in late 2026.

  • Retatrutide: a triple agonist that acts on GLP-1, GIP, and glucagon receptors. In the TRIUMPH-1 trial, the highest dose produced about 28 percent weight loss over 80 weeks among people who stayed on treatment. At that dose, more people stopped because of side effects than on placebo (about 11 versus 5 percent). It is not yet approved.

  • Survodutide: a GLP-1 and glucagon dual agonist with about 12 to 13 percent weight loss over 76 weeks in the phase 3 SYNCHRONIZE-1 trial (up to about 17 percent among people who stayed on treatment) and a strong effect on liver fat, making it a candidate for fatty liver disease.

  • Monthly injections and amylin-based drugs: several are in phase 3, including a monthly GLP-1 injection and amylin-based options designed to cause fewer digestive side effects.

Generic semaglutide

Semaglutide lost patent or data protection in several countries in 2026, including India, Canada, and Brazil. Lower-priced generic versions are now sold in India and Canada, and the first ones are starting to reach pharmacies in Brazil. In other countries, including the United States, the brand-name products remain protected for now. Buy only from licensed pharmacies with a prescription. Products sold online as "research peptides" or without a prescription are covered in Chapter 2 below and carry serious risks of contamination and wrong dosing.

What to Expect

Weeks 1 to 4
Dose titration and the highest likelihood of GI symptoms for GLP-1 drugs. Early appetite reduction is common. Expect modest early weight change.

Months 1 to 3
Assess response and tolerance. A practical benchmark is at least 5 percent body weight loss after 12 weeks on a therapeutic dose. If not achieved, consider a dose change, a different agent, or a deeper focus on nutrition, movement, and sleep.

Months 3 to 6
Weight loss is usually fastest in this window. Most people keep losing, more slowly, until a plateau at around 12 to 18 months.

Months 6 to 12 and beyond
Maintenance becomes the main task. Stopping medication often leads to regain unless lifestyle and behavior changes are firmly established. Many people will need ongoing therapy.

Response patterns

  • Good responders: 10 to 20 percent total loss, metabolic risk factors improve, side effects manageable.

  • Moderate responders: 5 to 10 percent loss. Consider adjuncts or program refinement.

  • Poor responders: less than 5 percent after 12 weeks at a therapeutic dose despite good adherence, or side effects that cannot be tolerated. Reassess the plan.

Who Should Consider Medication

Medical criteria

  • Body mass index at least 30, or at least 27 with a weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, osteoarthritis, or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD).

  • Documented lifestyle attempts without sufficient or durable success.

  • Willingness to pair medication with nutrition, activity, sleep, and behavior work.

Contraindications and cautions
Exact rules vary by medication, but include pregnancy and breastfeeding, medullary thyroid carcinoma or MEN2 for GLP-1 drugs, history of pancreatitis for some agents, seizure disorders for bupropion-containing regimens, uncontrolled hypertension for stimulants, significant GI disease for orlistat, and important drug interactions. Always review your full medication and supplement list with a clinician or pharmacist.

Special cases
For rare genetic forms of severe early-onset obesity, agents such as setmelanotide may be considered by specialists. It is also approved for Bardet-Biedl syndrome and, since March 2026, for acquired hypothalamic obesity after brain tumors or injury. This is specialist care.

Working With Your Healthcare Team

Before the visit
Bring weight history, prior attempts, current meds and supplements, family history, recent labs, and a short description of your diet, activity, sleep, stress, and readiness to change.

Smart questions

  • Which option best fits my medical profile and goals?

  • What weight change is realistic for me?

  • How long might I need to stay on it?

  • What side effects are most common and how will we manage them?

  • How will we judge success and safety, and how often will we follow up?

  • What will this cost me and are assistance programs available?

Monitoring
Expect monthly follow-up for the first 3 months, then every 3 months once stable. Check weight, blood pressure, heart rate, and targeted labs such as A1c, fasting lipids, renal and hepatic panels based on your situation. For GLP-1 users with prior retinopathy, include eye follow up.

Integrating Medication With Lifestyle

Nutrition

  • Maintain a calorie deficit appropriate for your age and health status.

  • Hit protein targets consistently to preserve lean mass.

  • Emphasize high-fiber, minimally processed foods.

  • With GLP-1s, smaller, more frequent meals and avoiding very fatty or greasy foods reduce nausea.

  • With orlistat, keep fat below about 30 percent of calories and take a multivitamin with vitamins A, D, E, and K at bedtime.

  • Hydrate well, especially during the first weeks of GLP-1 therapy.

Training

  • Prioritize resistance training 2 to 4 days per week to protect muscle.

  • Add Zone 2 cardio for cardiovascular health and recovery.

  • If using stimulant medications, monitor heart rate and avoid late-day dosing.

  • Start modestly while titrating doses, then progress.

Psychology and support
Plan for changes in appetite, social eating, and identity. Consider coaching or therapy, peer groups, and relapse-prevention strategies. Focus on routines, not willpower alone.

Age-Specific Notes

Ages 18 to 29
Lifestyle approaches are first line. Medications may be considered for severe obesity or comorbidity. Younger adults usually tolerate side effects better, but long horizons favor behavior first.

Ages 30 to 39
Common time to begin medication as work and family stress peak. Coordinate with family planning because many agents are contraindicated in pregnancy.

Ages 40 to 49
Comorbidities become more common. Screen for interactions and monitor blood pressure, glucose, and lipids. Perimenopause can change appetite and fat distribution; expectations should be realistic and program design individualized.

Ages 50+
Polypharmacy and organ function matter more. Review interactions, renal and hepatic function, fall risk, nutrition quality, and bone health. Close follow up is essential.

Quality, Legitimacy, and Cost

  • Prefer FDA-approved products from reputable manufacturers.

  • Avoid proprietary blends and nontransparent compounding. FDA declared the tirzepatide and semaglutide shortages over in December 2024 and February 2025, so mass-produced compounded copies are no longer permitted. Choose approved products.

  • Use one new medication at a time so you can judge effect and tolerance.

  • Budget for long-term use if the goal is long-term maintenance.

Setting Expectations and Planning Ahead

Short term, 3 to 6 months
Aim for about 5 to 10 percent loss, improvements in blood pressure, glucose, and lipids, and a stable routine for eating, activity, and sleep.

Long term, 1 to 2 years
Good responders may reach 10 to 20 percent or more with better health markers and quality of life. Maintenance usually requires continued medication and the behaviors you practiced during the loss phase.

If you stop
Expect some regain unless you have an intentional maintenance plan. Discuss tapering and a weight-maintenance blueprint before discontinuation.

Bottom line
Medications are tools that amplify a good program. The best results come from realistic goals, slow titration, consistent habits, and regular medical follow up. When you pair the right agent with the right lifestyle, you reduce risk, improve health, and make weight change more sustainable.

Bariatric Surgery: When It Is the Right Tool

For people with severe obesity, metabolic and bariatric surgery remains the most effective long-term treatment available. Even with the new generation of medications, surgery is the right choice for many people.

Who qualifies

International guidelines updated in 2022 by the leading surgical societies recommend surgery for:

  • A BMI of 35 or higher, regardless of whether weight-related diseases are present.

  • A BMI of 30 to 34.9 with metabolic disease, such as type 2 diabetes.

  • Lower thresholds for people of Asian descent, starting at a BMI of about 27.5.

Surgery can also be considered in carefully selected adolescents. Local criteria and insurance rules vary, so ask your doctor about your country's requirements.

The main procedures

  • Sleeve gastrectomy: about 75 to 80 percent of the stomach is removed, leaving a narrow tube. It reduces stomach capacity and changes hunger hormones. It is the most common procedure worldwide.

  • Roux-en-Y gastric bypass: a small stomach pouch is connected directly to the small intestine. It usually produces slightly more weight loss and a stronger effect on type 2 diabetes and reflux.

  • Other procedures: one-anastomosis gastric bypass, duodenal switch, and related procedures are used in specific situations. Gastric bands are rarely used today.

What to expect

Research Snapshot:
In the long-running Swedish Obese Subjects study of about 4,000 people, maximum weight loss after gastric bypass was about 32 percent at 1 to 2 years, stabilizing at about 25 percent after 10 years. People in the surgery group had a lower risk of death over the following decade than the matched control group, with fewer deaths from heart attacks and cancer.

  • Type 2 diabetes often goes into remission, especially when surgery is done early in the course of the disease.

  • Sleep apnea, high blood pressure, fatty liver, and joint pain usually improve.

The responsibilities that come with surgery

  • Lifelong vitamins and minerals: typically a multivitamin, vitamin B12, iron, calcium, and vitamin D, with regular blood tests. Deficiencies can cause anemia, bone loss, and nerve damage.

  • Protein first: at least 60 to 80 g of protein per day, often more, eaten before anything else at each meal.

  • Small meals, eaten slowly, and fluids separated from meals.

  • Alcohol: after gastric bypass, alcohol is absorbed faster and more strongly. The risk of alcohol use disorder rises, so alcohol should be limited or avoided.

  • Strength training is essential to protect muscle during rapid weight loss.

  • Some weight regain is common after 2 to 5 years. Follow-up with the surgical team, nutrition support, and, if needed, medication can help.

Surgery or medication?

Medications such as tirzepatide now produce weight loss that approaches that of sleeve gastrectomy for some people, but they must usually be continued long term. Surgery produces a one-time change with more durable results, but carries surgical risks and requires lifelong follow-up. Many centers now combine the two, using medication before surgery or to treat regain after it. The decision should be made with an experienced obesity team.

Chapter 2: Illegal and Gray-Market Substances

IMPORTANT DISCLAIMER: This part is for education only. This page does not recommend, endorse, or instruct on the use of illegal or unregulated substances. The purpose is to understand risks and legal exposure so you can avoid them and choose safer, legal alternatives.

Controlled substances: In the US, grouped into Schedules I to V under the Controlled Substances Act. Possession, distribution, or unsupervised use can carry fines and imprisonment.

Research chemicals: Often sold online as “not for human consumption.” Marketing or selling for ingestion violates FDA rules even if a compound is not scheduled. This includes unapproved GLP-1 research peptides such as retatrutide, targeted by FDA warning letters, and BPC-157, which has no approved human use. In July 2026 an FDA advisory committee voted to let pharmacies compound BPC-157, but this is not a drug approval and the FDA had not finalized it as of September 2026.

International variation: Legal status changes by country. Crossing borders with these substances can result in serious charges regardless of local legality at origin.

Anti-doping: WADA and most sporting bodies prohibit all categories in this chapter. Use leads to disqualification and bans.

Why These Substances Persist Underground

Pharmaceutical economics: Bringing a drug to market takes 10 to 15 years and costs in the billions. Cosmetic fat loss or physique enhancement rarely justifies that investment or passes risk-benefit review.

Regulatory hurdles: Approval demands consistent efficacy and acceptable safety. Many candidates show either modest benefits or unacceptable risks when used for non-medical goals.

Demand signals: Competitive sport, physique culture, and a quick-fix mindset sustain a market that legal medicine does not serve.

Major Categories and Core Risks

Anabolic-androgenic steroids

Status and background: In clinical use at physiological doses for specific conditions. In the US, anabolic steroids are Schedule III controlled substances, so possessing them without a valid prescription is illegal at any dose; many other countries also restrict them.

Why controlled:

  • Cardiovascular strain and increased risk of heart attack and stroke

  • Hepatic stress, especially with oral 17-alpha alkylated agents

  • Suppression of endogenous hormones, infertility, sexual dysfunction

  • Psychiatric effects including mood instability and aggression

  • Dependence potential and withdrawal

Examples:

  • Testosterone and derivatives: Therapeutic in hypogonadism under supervision. At high non-medical doses, risk escalates for cardio-metabolic and endocrine harm.

  • Trenbolone: Not approved for human use today. It is approved only as a cattle implant, and only in some countries; a human injectable once sold in France was withdrawn in 1997. Potent anabolic effects with severe cardiovascular, endocrine, and psychiatric side effects.

Selective androgen receptor modulators, SARMs

History: Developed since the 1990s for muscle wasting and osteoporosis. None are FDA approved for human use.

Current status: Sold as “research chemicals,” illegal to market for human consumption. Human data show testosterone suppression, liver enzyme elevations, and adverse lipid shifts. Online products are frequently adulterated or mislabeled.

Representative compounds and issues:

  • Ostarine, LGD-4033, RAD-140: Trials have shown hormone suppression and safety signals without durable, clinically meaningful advantages that would justify approval.

Why still available online: Loopholes, limited enforcement capacity, overseas manufacturing, and constantly churned variants.

Metabolic stimulants and uncouplers

2,4-Dinitrophenol, DNP: Industrial chemical briefly used for weight loss in the 1930s, then banned.

  • Mechanism uncouples oxidative phosphorylation.

  • Risks include uncontrollable hyperthermia and death. There is no antidote and the gap between an “effective” and lethal dose is narrow.

Clenbuterol: A bronchodilator approved for asthma in some countries but, in the US, only for horses.

  • Not approved for human use in the US; misuse carries risks of tachyarrhythmias, hypertension, and overdose.

  • Tolerance develops quickly, pushing dose escalation and risk.

Peptide hormones and growth factors

Human growth hormone, HGH: Prescription only for defined indications. In the United States, it is illegal to prescribe or distribute it for anti-aging or body composition in healthy adults; rules in other countries vary.

  • Risks include edema, insulin resistance, diabetes, carpal tunnel symptoms, and possible acceleration of malignancy.

IGF-1 and analogs: Recombinant IGF-1 (mecasermin) is approved only for a rare growth disorder in children; analogs such as IGF-1 LR3 are research chemicals never intended for human use.

  • Concerns include hypoglycemia, tumor promotion risk, and unknown long-term effects. Underground products have no quality control.

Health Risks at a Glance

Cardiovascular: Hypertension, arrhythmias, thrombosis, cardiomyopathy, atherosclerosis, and sudden death risk.

Liver and kidney: Hepatotoxicity with some orals and SARMs, cholestasis, elevated enzymes, and chronic kidney stress from increased protein turnover and dehydration.

Endocrine and fertility: Suppression of natural hormone axes, impaired spermatogenesis or ovulation, prolonged recovery, and sometimes incomplete reversal.

Neuropsychiatric: Anxiety, insomnia, aggression, depression, and increased risk of substance dependence.

Young users: Under 25s are at heightened risk due to still-maturing endocrine systems and longer lifetime exposure to long-term harms.

Quality and Supply Chain Problems

Adulteration and mislabeling: Underground products often contain different compounds or doses than the label claims.

Contamination: Heavy metals, solvents, microbes, and impurities from unregulated manufacturing.

Inconsistent dosing: Batch variability increases overdose and side effect risk even when users attempt conservative doses.

Legal, Career, and Financial Consequences

Criminal liability: Possession and distribution can lead to arrest, fines, and imprisonment.

Career impact: Professional licensure, security clearances, athletic eligibility, and employment can be jeopardized.

Financial fallout: Legal defense, lost income, medical bills, and replacement of seized goods far exceed any hoped-for physique benefit.

Prescription pathways: If medical criteria are met, work with a qualified clinician on approved weight management medications with known risk profiles and monitoring.

Evidence-based supplements: Protein powder, creatine, fiber, and caffeine used appropriately can offer small but real benefits.

Training and recovery systems: Periodized resistance training, adequate protein, sleep optimization, and stress management outperform any underground stack over the long run.

Hormone evaluation: If symptoms suggest deficiency, seek medical testing and supervised care, not black-market fixes.

Why the Risk-benefit Calculation Fails

Cognitive traps: Availability bias highlights success anecdotes, survivorship bias hides severe complications, and temporal discounting overvalues short-term appearance over long-term health.

Regulatory signal: If a compound were safe and effective for physique change, industry would have shepherded it through approval. The absence of approval is itself information about risk-benefit.

Age Lens - How Risk Amplifies by Decade

Ages 18 to 25: Highest risk of permanent endocrine disruption and impulsive dose escalation. Long runway for long-term harms to manifest.

Ages 26 to 35: Good baseline fitness can mask early warning signs. Legal trouble can derail career and family plans.

Ages 36 to 49: Comorbidities and medications increase interaction risks. Recovery from side effects is slower.

Ages 50+: Cardiovascular and hepatic risks rise sharply. Polypharmacy magnifies adverse events.

Bottom Line and Safer Path Forward

  • Underground substances exist because they fail medical risk-benefit or commercial viability for legal approval.

  • The combination of legal jeopardy, quality control failures, and serious health risks makes them a poor trade for any physique goal.

  • Sustainable results come from legal, supervised strategies: periodized training, adequate protein, sleep and stress management, and approved therapies when medically indicated.

  • If you are considering any substance for body composition, pause and consult a qualified clinician. Your long-term health, freedom, and finances are worth more than any short-term change in the mirror.

Coach’s note: The same discipline that tempts people toward shortcuts, when directed at training, nutrition, sleep, and patience, produces physiques and health that last.

References

  • Aronne, L. J., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26-36. https://doi.org/10.1056/NEJMoa2416394
  • Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., et al., & Kothari, S. N. (2022). 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for metabolic and bariatric surgery. Surgery for Obesity and Related Diseases, 18(12), 1345-1356. https://doi.org/10.1016/j.soard.2022.08.013
  • Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. The Lancet, 377(9774), 1341–1352. https://doi.org/10.1016/S0140-6736(11)60205-5
  • Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4
  • Grundlingh, J., Dargan, P. I., El-Zanfaly, M., & Wood, D. M. (2011). 2,4-Dinitrophenol (DNP): A weight loss agent with significant acute toxicity and risk of death. Journal of Medical Toxicology, 7(3), 205–212. https://doi.org/10.1007/s13181-011-0162-6
  • Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  • Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., et al. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 129(25 Suppl 2), S102–S138. https://doi.org/10.1161/01.cir.0000437739.71477.ee
  • Leciejewska, N., Jędrejko, K., Gómez-Renaud, V. M., Manríquez-Núñez, J., Muszyńska, B., & Pokrywka, A. (2024). Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases. European Journal of Clinical Pharmacology, 80(2), 185–202. https://doi.org/10.1007/s00228-023-03592-3
  • Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
  • Mohamed, W. T., Jahagirdar, V., Fatima, I., Ahmed, M., Jaber, F., Wang, K., Hassan, A. A., Ewing, E., Clarkston, W., & Likhitsup, A. (2023). Selective androgen receptor modulators (SARMs)-induced liver injury: A case report and review of literature. Cureus, 15(2), e35094. https://doi.org/10.7759/cureus.35094
  • Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl. 4), 16-27. https://doi.org/10.1111/dom.15728
  • Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
  • Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., et al., & Carlsson, L. M. S. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. New England Journal of Medicine, 357(8), 741-752. https://doi.org/10.1056/NEJMoa066254
  • Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
  • Wharton, S., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/NEJMoa2500969
  • Wharton, S., et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. https://doi.org/10.1056/NEJMoa2511774
  • Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Ozempic, Wegovy, Mounjaro, Zepbound and the other brand names on this page are trademarks of their respective owners. This site is independent: it is not affiliated with, sponsored by, or endorsed by any drug manufacturer.

Last updated: September 2026.